Ligand ID: PAR


Drugbank ID:
DB01421
(Paromomycin)


Indication:
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.

Get human targets for PAR in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'PAR' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.32A21.83
None
None
None
DMS  A1003 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.40A15.33
None
None
None
DMS  A 402 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6lzg ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
GLY B 476
TYR A  83
LEU A  97
GLU A  22
VAL A  93
1.55A23.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
SER B  10
GLU B 290
ASP B 295
1.42A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.40A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D   3
SER D 301
SER B 139
GLU B  14
1.80A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 159
SER C  10
GLU C 290
ASP C 295
1.39A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.37A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
SER A 549
SER A 814
ASP A 761
ASP A 618
1.47A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 8
SER C  10
SER C  15
ASP A 846
TYR A 420
1.73A12.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
PHE A 812
THR A 604
SER A 754
ASP A 608
GLY A 584
1.62A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.76A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 812
THR A 604
SER A 754
ASP A 608
GLY A 584
1.75A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
PHE A 812
THR A 604
SER A 754
ASP A 608
GLY A 584
1.61A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
ASP A 833
TYR A 831
HIS A 872
ASP A 879
GLU A 876
1.79A14.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
PHE C 802
PHE C 797
THR C 881
TYR C 789
GLY C 880
1.69A16.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE C 759
SER B1003
LEU B1001
THR B 998
ASP B 994
1.66A16.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR C 917
ASN C 914
THR C 912
GLY B1093
GLU B1092
1.75A13.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
PHE B 802
PHE B 797
THR B 881
TYR B 789
GLY B 880
1.75A15.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
PHE C 802
PHE C 797
THR C 881
TYR C 789
GLY C 880
1.74A15.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 858
THR C 859
SER C 735
ASP B 614
GLY B 593
1.67A15.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE C 377
SER C 366
THR C 385
ASP H 101
1.76A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE C 464
THR C 430
SER C 514
TYR L  92
1.76A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6w4b NSP9
(SARS-CoV-2)		5 / 10
TYR A  67
THR A  68
THR A  20
GLY A  18
ASP A  51
1.72A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w4h NSP16
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.56A18.85
None
None
None
SAM  A7102 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NDV_1_PAR13413_1
(25S RIBOSOMAL RNA
5S RIBOSOMAL RNA)		6w4h SARS-COV-2 NSP16
(SARS-CoV-2)		3 / 3
LYS A6968
GLU A7001
LYS A6844
0.89A10.29
ACT  A7103 ( 4.0A)
ACT  A7103 ( 4.1A)
ACT  A7103 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.59A
None
SAM  A7104 (-4.4A)
SAM  A7104 (-2.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.53A
None
None
None
SAM  A7104 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.56A19.02
None
None
None
SAM  A7102 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
PHE C6868
LEU C6883
THR C6880
TYR C6845
ASP C6904
1.57A19.02
None
None
None
SAM  C7105 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER D4325
SER C6872
ASP C6897
ASP C6895
1.69A16.67
None
SAM  C7105 ( 4.4A)
SAM  C7105 ( 2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
SER C6903
SER C6872
GLU C7001
ASP C6928
1.70A19.02
None
SAM  C7105 ( 4.4A)
FMT  C7108 ( 3.9A)
SAM  C7105 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.68A16.67
None
SAM  A7102 ( 4.6A)
SAM  A7102 ( 2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C 147
THR C 168
GLU C 161
TYR C 273
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B 147
THR B 168
GLU B 161
TYR B 273
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
THR C 102
SER C 103
GLU C 143
TYR C 136
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
THR B 102
SER B 103
GLU B 143
TYR B 136
1.61A
None
CL  B 502 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 147
THR A 168
GLU A 161
TYR A 273
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER A 103
THR A 115
ASP A 302
TYR C 268
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
PHE B 241
THR B 119
TYR B 136
GLU B 263
TYR B 273
1.73A19.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER B 103
THR B 115
ASP B 302
TYR A 268
1.40A
 CL  B 502 ( 4.4A)
CL  B 502 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B 304
THR B 115
ASP B 286
TYR B 264
1.49A
None
CL  B 502 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER C 103
THR C 115
ASP C 302
TYR B 268
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C 304
THR C 115
ASP C 286
TYR C 264
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE E 315
SER E 310
THR F 296
ASP F 297
TYR F 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE B 314
THR A 334
SER A 318
GLU A 323
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.75A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE A 286
THR A 296
ASP A 297
TYR A 268
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.76A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.74A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE C 314
THR D 334
SER D 318
GLU D 323
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE F 286
THR F 296
ASP F 297
TYR F 268
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE A 314
THR B 334
SER B 318
GLU B 323
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.63A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE C 315
SER C 310
THR D 296
ASP D 297
TYR D 268
1.65A12.05
None
None
CL  D 401 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE E 315
SER E 310
THR F 296
ASP F 297
TYR F 268
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.64A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE C 315
SER C 310
THR D 296
ASP D 297
TYR D 268
1.68A12.05
None
None
CL  D 401 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE C 286
THR C 296
ASP C 297
TYR C 268
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE E 286
THR E 296
ASP E 297
TYR E 268
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE E 315
SER E 310
THR F 296
ASP F 297
TYR F 268
1.66A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.74A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.66A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE C 315
SER C 310
THR D 296
ASP D 297
TYR D 268
1.63A
None
None
CL  D 401 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.63A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE B 286
THR B 296
ASP B 297
TYR B 268
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.63A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER D4325
SER C6872
ASP C6897
ASP C6895
1.56A
None
SAH  C7102 (-4.7A)
SAH  C7102 (-2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.61A
None
SAH  A7102 ( 4.6A)
SAH  A7102 (-2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.55A
None
None
None
SAH  A7102 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE C6868
LEU C6883
THR C6880
TYR C6845
ASP C6904
1.58A
None
None
None
SAH  C7102 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER D4325
SER C6872
ASP C6897
ASP C6895
1.65A
None
SFG  C7103 ( 4.5A)
SFG  C7103 ( 2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 8
SER C6903
SER C6872
GLU C7001
ASP C6928
1.66A
None
SFG  C7103 ( 4.5A)
None
SFG  C7103 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.65A
None
SFG  A7103 ( 4.5A)
SFG  A7103 ( 2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE C6868
LEU C6883
THR C6880
TYR C6845
ASP C6904
1.58A
None
None
None
SFG  C7103 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.56A
None
None
None
SFG  A7103 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.55A
None
None
None
SAH  A7101 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.60A
None
SO4  A7109 (-4.5A)
SAH  A7101 (-2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6wqd NSP7
(SARS-CoV-2)		3 / 3
SER C   1
LYS C   2
SER C   4
0.87A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6wqd NSP7
(SARS-CoV-2)		3 / 3
SER C   1
LYS C  -1
SER C   4
1.46A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
PHE A 147
THR A 168
GLU A 161
TYR A 273
1.59A
None
None
None
GOL  A 508 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
PHE A 304
THR A 115
ASP A 286
TYR A 264
1.37A
None
None
None
GOL  A 508 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6xip NSP7
(SARS-CoV-2)		3 / 3
SER A   1
LYS A   2
SER A   4
1.19A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.41A15.33
None
None
None
DMS  A 403 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
PHE D  92
THR C   9
ASP A   5
ASP C   5
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
SER C   1
LYS C   2
SER C   4
0.59A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
SER C  15
THR D  84
GLU D  77
ASP D  78
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
SER C  25
LYS C  27
SER C  26
1.36A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
PHE B  92
THR A   9
ASP C   5
ASP A   5
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A  29
TYR A  83
LEU A  73
TYR A  72
SER A  38
1.49A21.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 377
SER E 366
THR E 385
ASP H 107
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 377
SER A 366
THR A 385
ASP B 107
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
PHE A 515
THR B 104
TYR C  38
TYR B  32
GLY B 101
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 464
THR E 430
SER E 514
TYR L  98
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 464
THR A 430
SER A 514
TYR C  98
1.73A
None
None
None
DMS  C 303 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 464
THR E 430
SER E 514
TYR L  98
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 377
SER E 366
THR E 385
ASP H 107
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 377
SER E 366
THR E 385
ASP H 107
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 464
THR E 430
SER E 514
TYR L  98
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 377
SER A 366
THR A 385
ASP B 107
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 464
THR A 430
SER A 514
TYR C  98
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.35A
None
None
None
CL  A 406 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER E 167
SER C   7
ASP B  67
TYR B  42
1.56A
None
None
EDO  C 203 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER E 167
SER C   7
ASP B  67
TYR B  42
1.63A
None
None
EDO  B 203 ( 3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 214
TYR A 217
VAL A  71
TYR A  69
ASP A  67
1.34A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A  45
THR A 206
ASP A 221
TYR A 217
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
SER A 549
SER A 814
ASP A 761
ASP A 760
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
NSP7
(SARS-CoV-2)		5 / 12
PHE A 843
PHE A 415
LEU C  14
GLU C  47
ASP C  38
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A  70
THR A 120
SER A  68
GLU A 144
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
SER A 549
SER A 814
ASP A 761
ASP A 618
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		7btf NSP7
(SARS-CoV-2)		3 / 3
SER C   1
LYS C   2
SER C   4
0.69A18.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.61A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
THR A 540
SER A 561
ASP A 684
TYR A 453
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A  45
THR A 206
SER A 236
ASP A 221
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
SER A 784
GLU A 167
ASP A 161
ASP A 164
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 506
THR A 540
SER A 561
ASP A 684
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.69A12.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv2 NSP12
NSP7
(SARS-CoV-2)		4 / 8
PHE A 843
SER A 835
SER C   4
GLU C  47
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		7bv2 NSP7
(SARS-CoV-2)		3 / 3
SER C  25
LYS C  27
SER C  26
1.52A17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.79A12.43
None